Oncimmune’s CEO Martin Gouldstone spoke to Proactive and discussed the company’s latest achievements in an interview, highlighting a newly secured $700,000 contract with a major pharmaceutical company. This deal, which follows a significant $1.5 million contract announced in May 2024, underscores the growing commercial success of Oncimmune’s proprietary autoantibody profiling technology, particularly in the realm of immune-related diseases.
He also shared insights into Oncimmune’s expanding pipeline and emphasized the importance of these contracts as strong indicators of the company’s progress toward its strategic goals. He expressed confidence that these developments position Oncimmune to meet its full-year 2024 targets and achieve profitability by 2025. As part of its growth strategy, the company is also bolstering its commercial team, especially in the US market, to capitalize on these advancements.
These recent successes mark a pivotal moment in Oncimmune’s journey towards sustained profitability and long-term growth. Stay connected for more updates on Oncimmune’s continued progress and future milestones. Watch full interview below: